ATS 2019 Virtual Final Program

P559 Relapsing Polychondritis Patients with Tracheomalacia Have a Lower FEV1/FVC and FEF 25-75% as Well as a Previous Diagnosis of Asthma/ M. Ferrada, S. Kanth, A. Sirajuddin, J. Rosenblum, K. Gribbons, M. Chen, J. Katz, W. Goodspeed, N. Seam, J.H. Hansen-Flaschen, P.C. Grayson, Bethesda, MD, p.A4731 P560 Clinical Outcomes and Survival Following Lung Transplantation in Patients with Pulmonary Langerhans Cell Histiocytosis/ N.A. Wajda, Z. Zhu, R. Jandarov, N. Gupta, Cincinnati, OH, p.A4732 P561 Clinical Observation: 5 Cases of Wen San Ding Transdermal External Treatment for Idiopathic Pulmonary Alveolar Proteinosis/ B. Yang, Beijing, China, p.A4733 P562 Incidence of Pneumonitis and Pneumonia in Patients with Advanced Lung Cancer Treated with Programmed Death- Ligand 1 (PD-L1) Inhibitors/ P.P. Kyaw, S. Ball, M. Zaw, S. Swarup, N. Jahan, R. Sreedhar, J.Q. Henkle, K. Thein, Springfield, IL, p.A4734 P563 Sirolimus Related Lung Toxicity on Radiologic Evaluation/ F.M. Khateeb, R.M. Assaly, H.A. Badi, Toledo, OH, p.A4735 P564 Role of Infliximab in Immune Check Point Inhibitor Induced Pneumonitis/ K. Lai, V.R. Shannon, D. Balachandran, A. Sheshadri, L. Bashoura, S.A. Faiz, Houston, TX, p.A4736 P565 Clinical, Radiographic and Histopathologic Findings with Outcomes of Checkpoint Inhibitor Immunotherapy Induced Pneumonitis at Memorial Sloan Kettering Cancer Center (MSKCC)/ S. Imran, M.B. Feinstein, E. Khusainova, J. Sauter, D.E. Stover, New York, NY, p.A4737 P566 Effect of Ruxolitinib on Lung Function After Allogeneic Stem Cell Transplantation/ L. Bondeelle, S. Chevret, C. Hurabielle, F. Sicre de Fontbrune, D. Michonneau, A. Tazi, J.D. Bouaziz, A. Bergeron, Paris, France, p.A4738 Facilitator : E.A. Lendermon, MD, Pittsburgh, PA P567 Single Center Experience of ROSE+BALF+TBLB+NGS in Diagnose of Pneumocystis Pneumonia in Lung Transplant Recipients/ J. Zhang, Wuxi, China, p.A4739 P568 Post Lung Transplant Bronchial Stenosis: Disease Patterns, Interventions and Outcomes/ S.R. Ocheltree, G.A. Fernandez Romero, M. Kousha, O.A. O’Corragain, C. Dass, H. Zhao, N. Shigemura, Y. Toyoda, F.C. Cordova, G.J. Criner, M. Weir, Philadelphia, PA, p.A4740 P569 A Study to Evaluate the Association of Post-Transplant Lung Functions with Isolation of Non-Tuberculous Mycobacteria in Bronchoscopic Cultures During the First Year After Lung Transplantation/ C. Manthuruthil, F. Woll, R. La Hoz, M. Mohanka, J. Mullins, S. Bollineni, V. Kaza, F. Torres, A. Banga, Dallas, TX, p.A4741 P570 Sarcoidosis Outcomes on the Lung Transplantation Wait List in the Lung Allocation Score Era/ A. Gangemi, C.N. Myers, J.C. Brown, M. Butler-LeBair, E.R.A. Narewski, J. Galli, K.V. Shenoy, F.C. Cordova, N. Marchetti, G.J. Criner, R. Gupta, A.J. Mamary, Philadelphia, PA, p.A4742 P571 Clinical Utility of Bronchoalveolar Lavage Flow Cytometry in Lung Transplant Patients with Active Rejection - A Retrospective Study/ J.J. Lee, L. Wang, S. Wong, T. Kaleekal, S. Yau, Houston, TX, p.A4743 P572 Non-Alcoholic Fatty Liver Disease in Lung Transplant/ E. Male, H. Liaquat, N. Agrawal, A.J. Mamary, K. Carney, T. Bronzell-Wynder, G.J. Criner, P. Mulhall, Philadelphia, PA, p.A4744 P573 Predictors of Increased Length of ICU Stay Following Bilateral Lung Transplantation/ A. Chruscicki, L. Harper, V.K. Dhingra, J. Yee, C. Bergeron, R.G. Nador, J.R. Swiston, C. Rose, R.D. Levy, Vancouver, Canada, p.A4745 P574 Does Left Ventricular Assist Device Increase the Risk for Infections Over Time? A Phenotypic Evaluation/ R. Karnatak, K. Cawcutt, A. Kalil, T. Ryan, M. Moulton, A. Siddique, J. Um, U. Sandkovsky, Omaha, NE, p.A4746 P575 Acute Colonic Pseudo-Obstruction in Lung Transplant Recipients/ D. Djondo, K. Young, B. Bemiss, Maywood, IL, p.A4747 Facilitator : C. Johnson, MD, Philadelphia, PA P576 Clinical Characteristics Dermatomyositis/Polymyositis Associated Interstitial Lung Disease According to the Autoantibody/ T. Kishaba, Y. Nei, S. Ibuki, M. Momose, H. Nagano, S. Yamashiro, Uruma, Japan, p.A4748 P577 Methotrexate Leflunomide in the Treatment of Patients with Interstitial Lung Disease Positive to Antisynthetase Autoantibodies (Antisynthetase Syndrome)/ J. Mejia Hurtado, M.I. González Pérez, D.I. Pérez Roman, I. Buendia Roldán, M.E. Mejia Avila, R. Falfan Valencia, H.N. Mateos Toledo, J. Rojas Serrano, Mexico City, Mexico, p.A4749 P578 Trimethoprim/Sulfamethoxazole in Induced Alveolar Hemorrhage/ H. Zubair, S. Waheed, Z. Meer Rabeel, Buffalo, NY, p.A4750 P579 Analysis of Clinical Features by Both Diagnosis and Types of Antibodies in Patients with Myositis Related Interstitial Lung Disease: A Retrospective Multicenter Study/ Y. Waseda, A. Shiraki, K. Saeki, S. Watanabe, T. Shoda, T. Ishida, S. Makino, K. Tomii, T. Hase, Y. Hasegawa, M. Okamoto, S. Izumi, A. Miyamoto, K. Kishi, T. Kishaba, M. Nara, A. Komatsuda, M. Arita, K. Kawamura, K. Ichikado, Y. Koreeda, T. Mitsuma, Y. Hamaguchi, Y. Muro R. Egashira, H. Sumikawa, T. Ishizuka, T. Johkoh, Yoshida-gun, Japan, p.A4751 P580 The Change of CT Findings of Treatment in Anti-MDA5 Autoantibodies Positive Dermatomyositis and RP-ILD/ K. Yamaguchi, A. Yamaguchi, K. Hara, T. Maeno, N. Sunaga, Maebashi, Japan, p.A4752 P581 The Dartmouth-Hitchcock Pulmonary and Rheumatology Registry: An Initial Analysis/ J. Munchel, D. Dustin, J.D. Nuschke, D. Albert, A.H. Gifford, Lebanon, NH, p.A4753 P582 Long-Term Evaluation of Pulmonary Function Tests in Subgroups of Patients with Interstitial Pneumonia with Autoimmune Features/ J.A. Huapaya, B. Culotta, J. Fried, P. Bergquist, P. Krishnan, V. Steen, C. Reichner, Washington, DC, p.A4754 P583 Heart Rate Recovery in Patients with Scleroderma/ J. Fried, A. Hsu, C.A. Reichner, Washington, DC, p.A4755 ATS 2019 • Dallas, TX 250 TUESDAY • MAY 21